This adds important further evidence to the limited literature so far on roles for different biomarkers in a real‐world clinical cohort, with p‐tau217 being a very sensitive and specific test for AD and NfL having the strongest diagnostic performance to distinguish neurodegeneration from PPDs/non‐NDs, with little role for GFAP in any of these distinctions. This evidence concerns the gene NEFL and Alzheimer disease.